Gilead Sciences [GILD] vs Eli Lilly and [LLY] Detailed Stock Comparison

Gilead Sciences, Inc.

NASDAQ
Loading...

Eli Lilly and Company

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Gilead Sciences, Inc. wins in 9 metrics, Eli Lilly and Company wins in 12 metrics, with 0 ties. Eli Lilly and Company appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Gilead Sciences, Inc. Eli Lilly and Company Better
P/E Ratio (TTM) 19.66 40.09 Gilead Sciences, Inc.
Price-to-Book Ratio 7.29 31.01 Gilead Sciences, Inc.
Debt-to-Equity Ratio 112.92 165.31 Gilead Sciences, Inc.
PEG Ratio 0.85 0.79 Eli Lilly and Company
EV/EBITDA 12.44 26.61 Gilead Sciences, Inc.
Profit Margin (TTM) 28.90% 31.67% Eli Lilly and Company
Operating Margin (TTM) 37.38% 44.90% Eli Lilly and Company
EBITDA Margin (TTM) 37.38% 44.90% Eli Lilly and Company
Return on Equity 40.66% 101.16% Eli Lilly and Company
Return on Assets (TTM) 12.52% 19.42% Eli Lilly and Company
Free Cash Flow (TTM) $9.46B $5.96B Gilead Sciences, Inc.
Dividend Yield 2.57% 0.60% Gilead Sciences, Inc.
1-Year Return 14.19% 38.28% Eli Lilly and Company
Price-to-Sales Ratio (TTM) 5.62 12.63 Gilead Sciences, Inc.
Enterprise Value $181.31B $843.37B Eli Lilly and Company
EV/Revenue Ratio 6.16 12.94 Gilead Sciences, Inc.
Gross Profit Margin (TTM) 79.51% 82.52% Eli Lilly and Company
Revenue per Share (TTM) $24 $73 Eli Lilly and Company
Earnings per Share (Diluted) $6.78 $22.94 Eli Lilly and Company
Beta (Stock Volatility) 0.40 0.50 Gilead Sciences, Inc.
Short % of Float 1.74% 0.97% Eli Lilly and Company

Gilead Sciences, Inc. vs Eli Lilly and Company Stock Performance Analysis

Loading Price Chart...

GILD
LLY

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Gilead Sciences, Inc.-1.03%-2.97%-4.07%-14.40%3.77%2.22%
Eli Lilly and Company-0.32%-1.72%12.38%14.18%6.32%4.53%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Gilead Sciences, Inc.14.19%59.26%88.55%51.95%535.26%767.93%
Eli Lilly and Company38.28%153.07%418.42%1,433.98%2,935.09%1,988.48%

Performance & Financial Health Analysis: Gilead Sciences, Inc. vs Eli Lilly and Company

MetricGILDLLY
Market Information
Market Cap i$165.87B$821.31B
Market Cap CategoryLarge capMega cap
10 Day Avg. Volume i4,914,2122,387,476
90 Day Avg. Volume i5,711,5642,777,749
Last Close$124.30$1,129.35
52 Week Range$104.46 - $157.29$623.78 - $1,182.73
% from 52W High-20.97%-4.51%
All-Time High$157.27 (Feb 11, 2026)$1,182.73 (Jun 08, 2026)
% from All-Time High-20.96%-4.51%
Growth Metrics
Quarterly Revenue Growth0.05%0.43%
Quarterly Earnings Growth0.22%0.51%
Financial Health
Profit Margin (TTM) i0.29%0.32%
Operating Margin (TTM) i0.37%0.45%
Return on Equity (TTM) i0.41%1.01%
Debt to Equity (MRQ) i112.92165.31
Cash & Liquidity
Book Value per Share (MRQ)$18.29$29.66
Cash per Share (MRQ)$7.74$8.14
Operating Cash Flow (TTM) i$10.02B$16.81B
Levered Free Cash Flow (TTM) i$7.54B$1.95B
Dividends
Last 12-Month Dividend Yield i2.57%0.60%
Last 12-Month Dividend i$3.98$6.23

Valuation & Enterprise Metrics Analysis: Gilead Sciences, Inc. vs Eli Lilly and Company

MetricGILD (Apr 24, 2026)LLY (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i19.6640.09
Forward P/E i13.8521.82
PEG Ratio i0.850.79
Price to Sales (TTM) i5.6212.63
Price to Book (MRQ) i7.2931.01
Market Capitalization
Market Capitalization i$165.87B$821.31B
Enterprise Value i$181.31B$843.37B
Enterprise Value Metrics
Enterprise to Revenue i6.1612.94
Enterprise to EBITDA i12.4426.61
Risk & Other Metrics
Beta i0.400.50
Book Value per Share (MRQ) i$18.29$29.66

Financial Statements Comparison: Gilead Sciences, Inc. vs Eli Lilly and Company

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricGILD (2025)LLY (2025)
Revenue/Sales i29.44B65.18B
Cost of Goods Sold i6.23B11.05B
COGS % of Revenue i21.2%17.0%
Gross Profit i23.21B54.13B
Gross Margin i78.8%83.0%
Research & Development i5.80B13.34B
Operating Income (EBIT) i11.70B29.70B
Operating Margin i39.7%45.6%
EBITDA i14.81B35.09B
EBITDA Margin i50.3%53.8%
Pre-Tax Income i9.80B25.73B
Pre-Tax Income % of Revenue i33.3%39.5%
Income Tax i1.29B5.09B
Income Tax % of Revenue i4.4%7.8%
Net Income (Profit) i8.51B20.64B
Profit Margin i28.9%31.7%

Balance Sheet & Liquidity Metrics

MetricGILD (2025)LLY (2025)
Cash & Equivalents i7.56B7.27B
Total Current Assets i18.34B55.63B
Total Current Assets % of Revenue i62.3%85.3%
Total Current Liabilities i11.81B35.23B
Total Current Liabilities % of Revenue i40.1%54.0%
Long-Term Debt i22.13B40.87B
Long-Term Debt % of Revenue i75.2%62.7%
Total Shareholders Equity i22.62B26.54B
Retained Earnings i13.73B24.47B
Retained Earnings % of Revenue i46.6%37.5%
Property, Plant & Equipment i1.71B13.49B

Cash Flow Statement Comparison

MetricGILD (2025)LLY (2025)
Operating Cash Flow i10.19B23.60B
Operating Cash Flow % of Revenue i34.6%36.2%
Capital Expenditures i-563.00M-7.84B
Free Cash Flow i9.46B5.96B
FCF Margin i32.1%9.2%
Debt Repayment i-1.79B-778.00M
Common Stock Repurchase i-1.92B-4.11B

Short Interest & Institutional Ownership Analysis

MetricGILDLLY
Shares Short i21.52M7.70M
Short Ratio i3.562.73
Short % of Float i1.74%0.97%
Shares Outstanding i1.24B894.80M
Float Shares i1.24B890.99M
% Held by Insiders i0.13%0.17%
% Held by Institutions i92.71%84.77%
% Held by Public i7.16%15.06%

Dividend Analysis & Yield Comparison: Gilead Sciences, Inc. vs Eli Lilly and Company

MetricGILDLLY
Last 12-Month Dividend i$3.98$6.23
Last 12-Month Dividend Yield i2.57%0.60%
3-Year Avg Annual Dividend i$3.35$5.44
3-Year Avg Dividend Yield i0.85%0.18%
3-Year Total Dividends i$10.06$16.32
Ex-Dividend DateMar 13, 2026Feb 13, 2026